Les médicaments de la vessie

de Groat, 1993, Anatomy and physiology of the lower urinary tract, Urol Clin North Am, 20, 383, 10.1016/S0094-0143(21)00501-2 Roosen, 2009, A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature, Eur Urol, 56, 810, 10.1016/j.eururo.2009.07.044 Kanai, 2012, Mechanisms of action of botulinum neurotoxins, beta3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011, Neurourol Urodyn, 31, 300, 10.1002/nau.21246 Andersson, 2011, Antimuscarinic mechanisms and the overactive detrusor: an update, Eur Urol, 59, 377, 10.1016/j.eururo.2010.11.040 Novara, 2008, A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder, Eur Urol, 54, 740, 10.1016/j.eururo.2008.06.080 Kaplan, 2011, Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review, Int J Clin Pract, 65, 487, 10.1111/j.1742-1241.2010.02611.x Buser, 2012, Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses, Eur Urol, 62, 1040, 10.1016/j.eururo.2012.08.060 Madhuvrata, 2012, Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis, Eur Urol, 62, 816, 10.1016/j.eururo.2012.02.036 Wagg, 2012, Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience, BJU Int, 110, 1767, 10.1111/j.1464-410X.2012.11023.x Conquy, 2010, [Guidelines for the medical treatment of non-neurological urinary incontinence in women], Prog Urol, 20, S100, 10.1016/S1166-7087(10)70003-8 Lucas, 2012, EAU guidelines on assessment and nonsurgical management of urinary incontinence, Eur Urol, 62, 1130, 10.1016/j.eururo.2012.08.047 Descazeaud, 2012, [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association], Progn Urol, 22, 977, 10.1016/j.purol.2012.10.001 Oelke, 2013, EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction, Euro Urol, 64, 118, 10.1016/j.eururo.2013.03.004 Stohrer, 1999, Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia–a double-blind, placebo-controlled clinical trial, Spinal Cord, 37, 196, 10.1038/sj.sc.3100750 Stohrer, 2009, EAU guidelines on neurogenic lower urinary tract dysfunction, Eur Urol, 56, 81, 10.1016/j.eururo.2009.04.028 Campbell, 2009, The cognitive impact of anticholinergics: a clinical review, Clin Interv Aging, 4, 225 Fox, 2011, Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study, J Am Geriatr Soc, 59, 1477, 10.1111/j.1532-5415.2011.03491.x Chancellor, 2012, Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder, Drugs Aging, 29, 259, 10.2165/11597530-000000000-00000 Wagg, 2013, Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR Study, Eur Urol, 64, 74, 10.1016/j.eururo.2013.01.002 Khullar, 2013, Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial, Eur Urol, 63, 283, 10.1016/j.eururo.2012.10.016 Nitti, 2013, Results of a randomized phase III trial of mirabegron in patients with overactive bladder, J Urol, 189, 1388, 10.1016/j.juro.2012.10.017 Chapple, 2013, Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder, Eur Urol, 63, 296, 10.1016/j.eururo.2012.10.048 Caremel, 2010, Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat, Eur Urol, 58, 616, 10.1016/j.eururo.2010.07.026 Giuliano, 2013, The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia, Eur Urol, 63, 506, 10.1016/j.eururo.2012.09.006 McVary, 2007, Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial, J Urol, 177, 1071, 10.1016/j.juro.2006.10.055 Stief, 2008, A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia, Eur Urol, 53, 1236, 10.1016/j.eururo.2008.01.075 Oelke, 2012, Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial, Eur Urol, 61, 917, 10.1016/j.eururo.2012.01.013 Gacci, 2012, A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia, Eur Urol, 61, 994, 10.1016/j.eururo.2012.02.033 Giuliano, 2013, J Sex Med, 10, 857, 10.1111/jsm.12039 Behr-Roussel, 2012, Minimal effective dose of dysport and botox in a rat model of neurogenic detrusor overactivity, Eur Urol, 61, 1054, 10.1016/j.eururo.2012.01.051 Schurch, 2000, Treatment of neurogenic incontinence with botulinum toxin A, N Engl J Med, 342, 665, 10.1056/NEJM200003023420918 Schurch, 2000, Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs. Preliminary results, J Urol, 164, 692, 10.1016/S0022-5347(05)67283-7 Apostolidis, 2006, Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity, Eur Urol, 49, 644, 10.1016/j.eururo.2005.12.010 Duthie, 2011, Botulinum toxin injections for adults with overactive bladder syndrome, Cochrane Database Syst Rev, CD005493 Karsenty, 2008, Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review, Eur Urol, 53, 275, 10.1016/j.eururo.2007.10.013 Mangera, 2011, Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA), Eur Urol, 60, 784, 10.1016/j.eururo.2011.07.001 Reitz, 2007, Do repeat intradetrusor botulinum toxin type a injections yield valuable results. Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity, Eur Urol, 52, 1729, 10.1016/j.eururo.2007.08.052 Gaillet, 2012, Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity, Prog Urol, 22, 1064, 10.1016/j.purol.2012.10.006 Mohee, 2013, Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB), BJU Int, 111, 106, 10.1111/j.1464-410X.2012.11282.x Giannantoni, 2011, Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder, J Urol, 186, 960, 10.1016/j.juro.2011.04.071 Kuo, 2006, Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions, Urology, 67, 232, 10.1016/j.urology.2005.08.016 Game, 2009, Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review, J Pediatr Urol, 5, 156, 10.1016/j.jpurol.2009.01.005 Chapple, 2013, Onabotulinumtoxin A 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial, Eur Urol, 64, 249, 10.1016/j.eururo.2013.04.001 Denys, 2012, Efficacy and safety of low doses of onabotulinumtoxin A for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study, Eur Urol, 61, 520, 10.1016/j.eururo.2011.10.028 Gottsch, 2011, A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome, Neurourol Urodyn, 30, 93, 10.1002/nau.20946 Lee, 2013, Intravesical botulinum toxin A injections do not benefit patients with ulcer type interstitial cystitis, Pain Physician, 16, 109 Pinto, 2013, Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis, J Urol, 189, 548, 10.1016/j.juro.2012.09.027 Hanno, 2011, AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome, J Urol, 185, 2162, 10.1016/j.juro.2011.03.064 Game, 2008, Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections, Eur Urol, 53, 613, 10.1016/j.eururo.2007.08.039 van de Merwe, 2008, Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal, Eur Urol, 53, 60, 10.1016/j.eururo.2007.09.019 Kim, 2007, p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cells, FEBS Lett, 581, 3795, 10.1016/j.febslet.2007.06.058 Foster, 2010, Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome, J Urol, 183, 1853, 10.1016/j.juro.2009.12.106 van Ophoven, 2004, A prospective, randomized, placebo-controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis, J Urol, 172, 533, 10.1097/01.ju.0000132388.54703.4d van Ophoven, 2005, Long-term results of amitriptyline treatment for interstitial cystitis, J Urol, 174, 1837, 10.1097/01.ju.0000176741.10094.e0 Thilagarajah, 2001, Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial, BJU Int, 87, 207, 10.1046/j.1464-410x.2001.02031.x Perez-Marrero, 1988, A controlled study of dimethyl sulfoxide in interstitial cystitis, J Urol, 140, 36, 10.1016/S0022-5347(17)41478-9 Perez-Marrero, 1993, Prolongation of response to DMSO by heparin maintenance, Urology, 41, 64, 10.1016/0090-4295(93)90198-J Forrest, 2012, Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers, J Urol, 188, 1186, 10.1016/j.juro.2012.06.023 Sairanen, 2005, Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study, J Urol, 174, 2235, 10.1097/01.ju.0000181808.45786.84 Mulholland, 1990, Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study, Urology, 35, 552, 10.1016/0090-4295(90)80116-5 Parsons, 1987, Successful therapy of interstitial cystitis with pentosanpolysulfate, J Urol, 138, 513, 10.1016/S0022-5347(17)43243-5 Holm-Bentzen, 1987, A prospective double-blind clinically controlled multicenter trial of sodium pentosanpolysulfate in the treatment of interstitial cystitis and related painful bladder disease, J Urol, 138, 503, 10.1016/S0022-5347(17)43241-1 Sant, 2003, A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis, J Urol, 170, 810, 10.1097/01.ju.0000083020.06212.3d Bade, 1997, A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis, Br J Urol, 79, 168, 10.1046/j.1464-410X.1997.03384.x Daha, 2008, The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with bladder pain syndrome/interstitial cystitis: preliminary results, Int Urogynecol J Pelvic Floor Dysfunct, 19, 987, 10.1007/s00192-008-0560-8 van Koeveringe, 2011, Detrusor underactivity: a plea for new approaches to a common bladder dysfunction, Neurourol Urodyn, 30, 723, 10.1002/nau.21097 Barendrecht, 2007, Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based, BJU Int, 99, 749, 10.1111/j.1464-410X.2006.06742.x Deshpande, 2012, Drugs for nocturnal enuresis in children (other than desmopressin and tricyclics), Cochrane Database Syst Rev, 12, CD002238 Glazener, 2002, Desmopressin for nocturnal enuresis in children, Cochrane Database Syst Rev, CD002112 Kupelian, 2012, Nocturia and quality of life: results from the Boston area community health survey, Eur Urol, 61, 78, 10.1016/j.eururo.2011.05.065 Game, 2013, [Role of estrogens in lower urinary tract physiology and physiopathology], Prog Urol, 23, 502 Cody, 2012, Oestrogen therapy for urinary incontinence in post-menopausal women, Cochrane Database Syst Rev, 10, CD001405 Loibl, 2011, Management of menopausal symptoms in breast cancer patients, Maturitas, 68, 148, 10.1016/j.maturitas.2010.11.013